Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (179,894)	$ (155,597)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,714	16,747
Amortization and impairment of internal-use software	2,514	2,078
Stock-based compensation expense	74,840	59,430
Loss (gain) on disposal of property and equipment	(5)	4
Loss on disposition of Lemonaid Health Limited	2,026	0
Other operating activities	(504)	0
Changes in operating assets and liabilities:
Accounts receivable, net (includes related party amounts of $19 and $(50,001) for the six months ended September 30, 2023 and 2022, respectively)	396	(49,502)
Inventories	(4,733)	(3,017)
Deferred cost of revenue	(406)	914
Prepaid expenses and other current assets	(2,433)	4,899
Operating lease right-of-use assets	3,529	3,689
Other assets	664	(834)
Accounts payable (includes related party amounts of $(3,186)and $(8,915) for the six months ended September 30, 2023 and 2022, respectively)	(3,951)	(26,968)
Accrued expenses and other current liabilities (includes related party amounts of $4,993 and $(3,009) for the six months ended September 30, 2023 and 2022, respectively)	(5,674)	(10,367)
Deferred revenue (includes related party amounts of $(11,753) and $26,812 for the six months ended September 30, 2023 and 2022, respectively)	(22,237)	18,984
Operating lease liabilities	(4,255)	(4,426)
Other liabilities	(65)	(2,008)
Net cash used in operating activities	(126,474)	(145,974)
Cash flows from investing activities:
Purchases of property and equipment	(715)	(1,945)
Proceeds from sale of property and equipment	5	2
Capitalized internal-use software costs	(4,758)	(3,008)
Net cash used in investing activities	(5,468)	(4,951)
Cash flows from financing activities:
Proceeds from exercise of stock options	473	3,944
Proceeds from issuance of common stock under employee stock purchase plan	1,411	3,238
Payments of deferred offering costs	(263)	0
Payments for taxes related to net share settlement of equity awards	(142)	0
Net cash provided by financing activities	1,479	7,182
Effect of exchange rates on cash and cash equivalents	0	1,452
Net decrease in cash, cash equivalents and restricted cash	(130,463)	(142,291)
Cash, cash equivalents and restricted cash-beginning of period	395,222	561,755
Cash, cash equivalents and restricted cash-end of period	264,759	419,464
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	26	762
Stock-based compensation capitalized for internal-use software costs	2,089	1,320
Cash and cash equivalents	256,386	410,891
Restricted cash, current	1,399	1,599
Restricted cash, noncurrent	6,974	6,974
Total cash, cash equivalents and restricted cash	$ 264,759	$ 419,464